Citigroup Maintains Neutral on ResMed, Raises Price Target to $270
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.